Payment overview · 2025
General Payments
$695.00
32 reported records · 13 companies
Healthcare provider profile · identity verified
Mackenzie J Hemje, MD
Allopathic & Osteopathic Physicians|Family Medicine · HASTINGS, NE · NPI 1700291085
Verified facts
What the public records show
CMS Open Payments records show Mackenzie J Hemje, MD received $695.00 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $219.58 | 31.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $173.71 | 25.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.26 | 6.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.50 | 6.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.62 | 5.4% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $37.24 | 5.4% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $32.48 | 4.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.09 | 4.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.09 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.85 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.21 | 2.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.98 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.39 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $695.00 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $211.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $205.62 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $197.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.32 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $83.39 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $83.39 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.68 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.26 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $43.50 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.88 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.62 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 46 |
| Simvastatin | Simvastatin | 245 | 62 |
| Potassium Chloride | Potassium Chloride | 243 | 48 |
| Omeprazole | Omeprazole | 231 | 52 |
| Lisinopril | Lisinopril | 222 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 50 |
| Furosemide | Furosemide | 208 | 44 |
| Losartan Potassium | Losartan Potassium | 198 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 48 |
| Metformin Hcl Er | Metformin Hcl | 158 | 43 |
| Montelukast Sodium | Montelukast Sodium | 156 | 33 |
| Sertraline Hcl | Sertraline Hcl | 147 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 32 |
| Eliquis | Apixaban | 120 | 15 |
| Allopurinol | Allopurinol | 118 | 30 |
| Warfarin Sodium | Warfarin Sodium | 94 | 14 |
| Tramadol Hcl | Tramadol Hcl | 93 | 20 |
| Ozempic | Semaglutide | 91 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 21 |
| Lorazepam | Lorazepam | 77 | 14 |
| Prednisone | Prednisone | 68 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 16 |
| Gabapentin | Gabapentin | 64 | 20 |
| Enalapril Maleate | Enalapril Maleate | 63 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 15 |
| Meloxicam | Meloxicam | 59 | 26 |
| Glipizide Er | Glipizide | 56 | 13 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 14 |
| Metformin Hcl | Metformin Hcl | 49 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 11 |
| Valsartan | Valsartan | 45 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 11 |
| Alendronate Sodium | Alendronate Sodium | 43 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 35 | 35 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Cephalexin | Cephalexin | 32 | 26 |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 16 |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 18 |
| Estradiol | Estradiol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $695.00 · 32 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BEYFORTUS, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, FARXIGA, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, M-M-R II, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, PROQUAD, QULIPTA, ROTATEQ, UBRELVY, VAXNEUVANCE, VOQUEZNA, Xhance, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error